Comparing two treatment plans for locally advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares two treatment plans for stage III lung cancer that can't be removed by surgery. It tests whether starting with a combination of immunotherapy, targeted therapy, and chemotherapy before usual chemoradiation works better than the usual approach, and whether continuing immunotherapy after treatment helps people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have stage III non-small cell lung cancer that cannot be removed with surgery
- Be in generally good physical condition (able to do light work)
- Have not had chemotherapy, targeted therapy, or radiation to your chest before
- Have a tumor sample available or be willing to provide one for testing
- No other active cancer in the last 5 years, except certain easily treated skin or other early-stage cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests two drugs, benmelstobart (immunotherapy) and anlotinib (a targeted therapy), alone or combined, before surgery for non-small cell lung cancer. The goal is to see if these drugs shrink the tumor enough to improve the chances of a complete response after surgery.
This trial tests a new combination of two drugs (bempemab and anlotinib) as a first treatment for older adults with advanced lung cancer. The goal is to see if this drug pair can shrink tumors and slow the cancer, possibly without the need for chemo or radiation.
This trial tests a combination of radiation and immunotherapy to see if it can make the immune system attack cancer throughout the body in people with advanced lung cancer that has spread to many places. It's for those whose cancer does not have certain genetic changes and who have not had uncontrolled brain metastases.
This trial tests a combination of an immunotherapy drug (benmelstobart) with chemotherapy, and sometimes another drug (anlotinib), for people with limited-stage small cell lung cancer. The goal is to see if this treatment helps shrink or control the cancer before surgery.
This trial tests whether giving the immunotherapy drug Benmelstobart after surgery can help prevent return of a specific type of lung cancer. It is for people with stage IB, grade 3 (poorly differentiated) lung adenocarcinoma that has been completely removed.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.